Cargando…
Human GLB1 knockout cerebral organoids: A model system for testing AAV9-mediated GLB1 gene therapy for reducing GM1 ganglioside storage in GM1 gangliosidosis
GM1 gangliosidosis is an autosomal recessive neurodegenerative disorder caused by the deficiency of lysosomal β-galactosidase (β-gal) and resulting in accumulation of GM1 ganglioside. The disease spectrum ranges from infantile to late onset and is uniformly fatal, with no effective therapy currently...
Autores principales: | Latour, Yvonne L., Yoon, Robin, Thomas, Sarah E., Grant, Christina, Li, Cuiling, Sena-Esteves, Miguel, Allende, Maria L., Proia, Richard L., Tifft, Cynthia J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744524/ https://www.ncbi.nlm.nih.gov/pubmed/31534909 http://dx.doi.org/10.1016/j.ymgmr.2019.100513 |
Ejemplares similares
-
Sialidase NEU3 action on GM1 ganglioside is neuroprotective in GM1 gangliosidosis
por: Allende, Maria L., et al.
Publicado: (2023) -
Protein modeling and clinical description of a novel in‐frame GLB1 deletion causing GM1 gangliosidosis type II
por: Richter, John E., et al.
Publicado: (2018) -
Case reports of juvenile GM1 gangliosidosisis type II caused by mutation in GLB1 gene
por: Karimzadeh, Parvaneh, et al.
Publicado: (2017) -
GM1 Gangliosidosis—A Mini-Review
por: Nicoli, Elena-Raluca, et al.
Publicado: (2021) -
Pre-diagnosing and managing patients with GM1 gangliosidosis and related disorders by the evaluation of GM1 ganglioside content
por: Tonin, Rodolfo, et al.
Publicado: (2019)